Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

01-12-2020 | Thyroid Disease | Research article

The association between albuminuria and thyroid antibodies in newly diagnosed type 2 diabetes mellitus patients with Hashimoto’s thyroiditis and euthyroidism

Authors: Wei Zhu, Xuejie Dong, Qingrong Pan, Yanjin Hu, Guang Wang

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Microalbuminuria is a prognostic marker of diabetes kidney disease. It is generally diagnosed as the ratio of urinary albumin to creatinine (UACR) of 30-300 mg/g. Hashimoto’s thyroiditis is a common disease in the endocrinology and the thyroid antibodies may associated with kidney disease. We investigated the UACR in the newly diagnosed T2DM with Hashimoto’s thyroiditis and tried to detect the relationship between the UACR and thyroid antibodies.

Methods

One hundred twenty newly diagnosed T2DM patients with Hashimoto’s thyroiditis and euthyroidism and 50 sex and age-matched T2DM with non-Hashimoto’s and other thyroid disease were recruited. T2DM patients were divided into 2 groups by the titer of TPOAb: (1). TPOAb (+) group: T2DM with positive TPOAb (n = 105); (2). TPOAb (−) group: T2DM with negative TPOAb (n = 65).

Results

T2DM with positive TPOAb group had higher UACR than T2DM with negative TPOAb group (21.55 ± 7.28 vs 15.13 ± 5.69 mg/g, P < 0.01). UACR were positively related to BMI (r = 0.255, P < 0.05), FPG (r = 0.285, P < 0.05), HbA1c (r = 0.260, P < 0.05) and TPOAb (r = 0.349, P < 0.05). HbA1c (β = 0.793, P < 0.05), BMI (β = 0.342, P < 0.05) and lnTPOAb (β = 1.207, P < 0.05) were independently associated with UACR.

Conclusions

In the newly diagnosed T2DM patients, Hashimoto’s thyroiditis with TPOAb positive had higher UACR levels. TPOAb titer, BMI and HbA1c were independent associated with UACR in these patients.
Literature
2.
go back to reference de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007;27(2):172–81.PubMedCrossRef de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol. 2007;27(2):172–81.PubMedCrossRef
3.
4.
go back to reference Tanaka F, Komi R, Makita S, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016;34(3):506–12.PubMedCrossRef Tanaka F, Komi R, Makita S, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016;34(3):506–12.PubMedCrossRef
5.
go back to reference Pan Q, Xu Y, Yang N, et al. Metformin or Acarbose treatment significantly reduced albuminuria in patients with newly diagnosed type 2 diabetes mellitus and low-grade albuminuria. Med Sci Monit. 2018;24:8941–9.PubMedPubMedCentralCrossRef Pan Q, Xu Y, Yang N, et al. Metformin or Acarbose treatment significantly reduced albuminuria in patients with newly diagnosed type 2 diabetes mellitus and low-grade albuminuria. Med Sci Monit. 2018;24:8941–9.PubMedPubMedCentralCrossRef
6.
go back to reference Elyas S, Angela C Shore, Hayley Kingwell, et al. Microalbuminuria could improve risk stratification in patients with TIA and minor stroke. Ann Clin Transl Neurol. 2016;3(9):678–83.PubMedPubMedCentralCrossRef Elyas S, Angela C Shore, Hayley Kingwell, et al. Microalbuminuria could improve risk stratification in patients with TIA and minor stroke. Ann Clin Transl Neurol. 2016;3(9):678–83.PubMedPubMedCentralCrossRef
7.
go back to reference Association AD. Improving care and promoting health in populations: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S7–S13.CrossRef Association AD. Improving care and promoting health in populations: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S7–S13.CrossRef
8.
go back to reference Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in north-eastern Sicily and Calabria (southern Italy) based on a 31-year experience. Thyroid. 2008;18(4):429–41.PubMedCrossRef Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in north-eastern Sicily and Calabria (southern Italy) based on a 31-year experience. Thyroid. 2008;18(4):429–41.PubMedCrossRef
10.
go back to reference Jordan SC, Buckingham B, Sakai R, et al. Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. N Engl J Med. 1981;304(20):1212–5.PubMedCrossRef Jordan SC, Buckingham B, Sakai R, et al. Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. N Engl J Med. 1981;304(20):1212–5.PubMedCrossRef
11.
go back to reference Hong JW, Ku CR, Noh JH, et al. Association between low-grade albuminuria and cardiovascular risk in Korean adults: the 2011-2012 Korea National Health and nutrition examination survey. PLoS One. 2015 Mar 5;10(3):e0118866.PubMedPubMedCentralCrossRef Hong JW, Ku CR, Noh JH, et al. Association between low-grade albuminuria and cardiovascular risk in Korean adults: the 2011-2012 Korea National Health and nutrition examination survey. PLoS One. 2015 Mar 5;10(3):e0118866.PubMedPubMedCentralCrossRef
12.
go back to reference DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. Lancet Diabetes Endocrinol. 2014;2(10):793–800.CrossRef DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study. Lancet Diabetes Endocrinol. 2014;2(10):793–800.CrossRef
13.
go back to reference Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care. 2000;23(10):1478–85.PubMedCrossRef Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans affairs cooperative study on glycemic control and complications in type 2 diabetes feasibility trial investigators. Diabetes Care. 2000;23(10):1478–85.PubMedCrossRef
14.
go back to reference Iglesias P, Bajo MA, Selgas R, et al. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disord. 2017;18(1):131–44.PubMedCrossRef Iglesias P, Bajo MA, Selgas R, et al. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disord. 2017;18(1):131–44.PubMedCrossRef
15.
go back to reference Xie J, Wang X, Zhang Y, et al. The longitudinal effect of subclinical hypothyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2019;19(1):84.PubMedPubMedCentralCrossRef Xie J, Wang X, Zhang Y, et al. The longitudinal effect of subclinical hypothyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2019;19(1):84.PubMedPubMedCentralCrossRef
16.
go back to reference O'Regan S, Fong JS, Kaplan BS, et al. Thyroid antigen-antibody nephritis. Clin Immunol Immunopathol. 1976;6(3):341–6.PubMedCrossRef O'Regan S, Fong JS, Kaplan BS, et al. Thyroid antigen-antibody nephritis. Clin Immunol Immunopathol. 1976;6(3):341–6.PubMedCrossRef
17.
go back to reference Santoro D, Vadalà C, Siligato R, et al. Autoimmune Thyroiditis and Glomerulopathies. Front Endocrinol (Lausanne). 2017;8:119.CrossRef Santoro D, Vadalà C, Siligato R, et al. Autoimmune Thyroiditis and Glomerulopathies. Front Endocrinol (Lausanne). 2017;8:119.CrossRef
18.
go back to reference Xiang GD, He YS, Zhao LS, et al. Impairment of endothelium-dependent arterial dilation in Hashimoto's thyroiditis patients with euthyroidism. Clin Endocrinol. 2006;64(6):698–702.CrossRef Xiang GD, He YS, Zhao LS, et al. Impairment of endothelium-dependent arterial dilation in Hashimoto's thyroiditis patients with euthyroidism. Clin Endocrinol. 2006;64(6):698–702.CrossRef
19.
go back to reference Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–5.PubMedCrossRef Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–5.PubMedCrossRef
20.
go back to reference Man REK, Gan ATL, Fenwick EK, et al. The Relationship between Generalized and Abdominal Obesity with Diabetic Kidney Disease in Type 2 Diabetes: A Multiethnic Asian Study and Meta-Analysis. Nutrients. 2018;10(11):E1685.PubMedCrossRef Man REK, Gan ATL, Fenwick EK, et al. The Relationship between Generalized and Abdominal Obesity with Diabetic Kidney Disease in Type 2 Diabetes: A Multiethnic Asian Study and Meta-Analysis. Nutrients. 2018;10(11):E1685.PubMedCrossRef
21.
go back to reference Belhatem N, Mohammedi K, Rouzet F, et al. Impact of morbid obesity on the kidney function of patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108(1):143–9.PubMedCrossRef Belhatem N, Mohammedi K, Rouzet F, et al. Impact of morbid obesity on the kidney function of patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108(1):143–9.PubMedCrossRef
22.
23.
go back to reference Cao L, Boston A, Jegede O, et al. Inflammation and kidney injury in diabetic African American men. J Diabetes Res. 2019;2019:5359635.PubMedPubMedCentral Cao L, Boston A, Jegede O, et al. Inflammation and kidney injury in diabetic African American men. J Diabetes Res. 2019;2019:5359635.PubMedPubMedCentral
24.
go back to reference Fathy SA, Mohamed MR, Ali MAM, et al. Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers. 2019;24(1):43–55.PubMedCrossRef Fathy SA, Mohamed MR, Ali MAM, et al. Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers. 2019;24(1):43–55.PubMedCrossRef
25.
go back to reference Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med. 2017;8(1):41–9.PubMedPubMedCentralCrossRef Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med. 2017;8(1):41–9.PubMedPubMedCentralCrossRef
26.
go back to reference Martínez-García C, Izquierdo-Lahuerta A, Vivas Y, et al. Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton Organization in Podocytes. PLoS One. 2015;10(11):e0142291.PubMedPubMedCentralCrossRef Martínez-García C, Izquierdo-Lahuerta A, Vivas Y, et al. Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton Organization in Podocytes. PLoS One. 2015;10(11):e0142291.PubMedPubMedCentralCrossRef
Metadata
Title
The association between albuminuria and thyroid antibodies in newly diagnosed type 2 diabetes mellitus patients with Hashimoto’s thyroiditis and euthyroidism
Authors
Wei Zhu
Xuejie Dong
Qingrong Pan
Yanjin Hu
Guang Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00650-0

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.